2018, 上原記念財団海外留学助成リサーチフェローシップ　　　　　　　　　　　　　　　

2017, 北海道大学大学院医学研究科・医学部医学科 優秀論文賞　　　　　　　　　　　　　　　

Successful treatment of huntingtin-interacting protein-1-anaplastic lymphoma kinase-positive lung cancer with severe airway stenosis using silicone stent placement and alectinib.
Sato Y, Kitai H, Takashima Y, Shinagawa N, Sakakibara-Konishi J, Ohkawa H, Hatanaka KC, Hatanaka Y, Yokouchi H, Konno S
Respiratory investigation, 11 Nov. 2025
Scientific journal, Huntingtin-interacting protein 1 (HIP1)-anaplastic lymphoma kinase (ALK) is a relatively rare fusion in ALK-positive lung cancers. HIP1-ALK (H19:A20) is a rare variant among HIP1-ALK-positive lung cancers, and data on the efficacy of ALK tyrosine kinase inhibitors are limited. We report a 37-year-old man with HIP1-ALK (H19:A20) lung adenocarcinoma treated with silicone stent placement and alectinib. Stent placement was effective in improving symptoms, and the best treatment response with alectinib was a partial response. Routine ALK screening using IHC or comprehensive genomic profiling should be considered for patients with lung cancer with suspected ALK gene.

Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab
Sawana Ono, Hirokazu Taniguchi, Koji Kuroda, Teppei Hashimoto, Asuka Okada, Yasuhiro Goto, Hidenori Kitai, Yoichi Nakamura, Shinsuke Ogusu, Tetsunari Hase, Takayo Ota, Noriyuki Ebi, Makoto Furugen, Taishi Harada, Yoshiaki Kinoshita, Takaki Mizoguchi, Katsumi Nakatomi, Yoshifumi Soejima, Takahiro Yamada, Shinnosuke Takemoto, Hiroshi Mukae
Lung Cancer, Sep. 2025
Scientific journal

Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.
Daisuke Morinaga, Jun Sakakibara-Konishi, Kamada R, Kashima M, Tsuji K, Ito S, Furuta M, Shoji T, Takashima Y, Kitai H, Ikezawa Y, Taguchi H, Kato T, Shinomiya Y, C Hatanaka K, Hatanaka Y, Konno S
Thoracic cancer, 01 Jul. 2025
Scientific journal,

Background

During the systemic treatment of patients with non-small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention. Traditionally, systemic therapy is continued after disease progression; however, advancements in local ablation therapy (LAT), such as radiotherapy and surgery, have demonstrated clinical efficacy in patients with OP. The characteristics of patients who may benefit from LAT or their genetic background remain unclear. This study evaluated the frequency, clinicopathological characteristics, and efficacy of LAT in the treatment of OP.

Methods

A retrospective review was conducted of 510 patients with NSCLC who experienced disease progression after systemic therapy.

Results

Overall, 106/510 (23.6%) patients exhibited OP; among these, six patients who received only the best supportive care after OP were excluded. Systemic therapy alone was administered to 79 patients (79.0%), while 21 (21.0%) received LAT. Median local progression-free survival was numerically longer in the LAT group than in the systemic therapy-only group (8.3 and 6.7 months, respectively; p = 0.38). In addition, overall survival was also numerically longer in the LAT group than in the systemic therapy-only group (78.1 and 55.1 months, respectively; p = 0.57). Ribonucleic acid sequencing revealed an increase in extracellular matrix-related gene expression after OP, providing potential molecular insights.

Conclusions

Although this study found no significant prognostic benefit of LAT in patients with OP, future research integrating clinical and molecular data may identify patients most likely to benefit from LAT.

Midkine Promotes Tumor Growth and Attenuates the Effect of Cisplatin in Small Cell Lung Cancer.
Ito S, Jun Sakakibara-Konishi, Sato M, Shoji T, Furuta M, Takahashi H, Tsuji K, Daisuke Morinaga, Kashima M, Kitai H, Kikuchi J, Kikuchi E, Hatanaka KC, Hatanaka Y, Kyoko Hida, Noguchi T, Konno S
Cancer medicine, 01 Jul. 2025
Scientific journal,

Purpose

Small cell lung cancer (SCLC) is a highly aggressive disease associated with poor patient survival rates. The addition of an anti-programmed death ligand 1 antibody to platinum combination chemotherapy can improve its prognosis. However, only a few patients achieve a long-term response; thus, establishing new therapies for SCLC is crucial. Midkine (MDK) is a heparin-binding growth factor involved in various biological processes, including cell proliferation and chemotherapeutic resistance, in diverse cancers. MDK has garnered attention as a therapeutic and diagnostic target for several cancers; however, only a few studies have evaluated its expression and function in SCLC. This study aimed to evaluate the MDK expression in human SCLC tissue and human SCLC cell lines, and to clarify its function in tumorigenesis.

Methods

MDK expression was analyzed in vitro and in vivo through ELISA, immunohistochemistry, and western blotting. Its effects on cell proliferation, as well as the effects of cisplatin, were evaluated using the MTT assay.

Results

MDK was pathologically expressed in human SCLC tumor tissues but not in normal lung tissues. Serum MDK concentrations in patients with SCLC reflected the SCLC tumor burden and were correlated with response to treatment. Moreover, MDK induced cell proliferation and attenuated the effects of cisplatin in SCLC cell lines. An MDK inhibitor and cisplatin exerted synergistic antitumor effects both in vitro and in vivo. Furthermore, MDK positively regulated the AKT pathway.

Conclusion

Our findings indicate that MDK promotes cell proliferation and chemotherapeutic resistance by activating the AKT pathway in SCLC cells. Therefore, MDK may be a potential therapeutic and diagnostic target for SCLC.

Efficacy of second line and subsequent treatments of small cell lung cancer with and without immune checkpoint inhibitor combination therapy
Daisuke Morinaga, Jun Sakakibara-Konishi, Yasutaka Kawai, Yumi Morinaga, Shohei Mizobuchi, Yoshihiro Okamoto, Yasunari Yamanaka, Kei Takahashi, Hajime Kikuchi, Noriaki Sukoh, Taichi Takashina, Hidenori Kitai, Satoshi Konno
Respiratory Investigation, May 2025
English, Scientific journal

Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report.
Hatakeyama Y, Sakakibara-Konishi J, Tarumi M, Tsuji K, Takahashi H, Furuta M, Takashima Y, Kitai H, Shoji T, Ikezawa Y, Konno S
Respiratory medicine case reports, 15 Feb. 2025
Scientific journal, Based on the results of a multicenter phase II study of patients with previously treated thymic carcinoma, lenvatinib administration for unresectable thymic cancer has been covered under insurance in Japan since 2021. However, patients with interstitial lung disease (ILD) were excluded from that study; therefore, the efficacy and safety of lenvatinib in these patients remain unknown. Herein, we report the case of a woman in her 50s who was diagnosed with thymic carcinoma complicated with ILD. In August 2016, the patient developed ILD with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM). She received triple therapy comprising prednisolone, tacrolimus and azathioprine. In October 2021, the patient complained of lateral chest pain and back pain. In January 2022, computed tomography (CT) revealed an anterior mediastinal tumor, and percutaneous biopsy resulted in a diagnosis of thymic carcinoma with Masaoka classification IVb. In March 2022, first-line treatment with four cycles of carboplatin (area under the curve, 6) + paclitaxel (200 mg/m²) was initiated. Although a partial response was achieved, in September 2022, CT demonstrated progressive disease (PD). Therefore, in October 2022, Lenvatinib (24 mg) was started as the second-line treatment. The best response was stable disease; moreover, although lenvatinib dose reduction was required owing to adverse events, such as biliary-tract infection and stomatitis. The patient did not experience ILD exacerbation. Lenvatinib (14 mg) was continued until PD was observed in March 2023. Our findings suggest that lenvatinib is a viable treatment option for thymic carcinoma with ILD.

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
Jun Sakakibara-Konishi, Hirofumi Takahashi, Kenichiro Ito, Tomoo Ikari, Yasuyuki Ikezawa, Hidenori Kitai, Megumi Furuta, Yuta Takashima, Tetsuaki Shoji, Masahide Fukudo, Satoshi Konno
Respiratory Medicine Case Reports, 53, 102176, 102176, Elsevier BV, 2025
Scientific journal

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
Yamamoto G, Tanaka K, Kamata R, Saito H, Yamamori-Morita T, Nakao T, Liu J, Mori S, Yagishita S, Hamada A, Shinno Y, Yoshida T, Horinouchi H, Ohe Y, Watanabe SI, Yatabe Y, Kitai H, Konno S, Kobayashi SS, Ohashi A
Cancer letters, 24 Dec. 2024
Scientific journal, KRAS^G12C inhibitors sotorasib and adagrasib have been approved for the treatment of KRAS^G12C-mutant non-small cell lung cancer (NSCLC). However, the efficacy of single-agent treatments is limited, presumably due to multiple resistance mechanisms. To overcome these therapeutic limitations, combination strategies that potentiate the antitumor efficacy of KRAS^G12C inhibitors must be developed. Through unbiased high-throughput screening of 1395 kinase inhibitors, we identified adavosertib, a WEE1 inhibitor, as a promising combination partner of sotorasib. The combination of sotorasib and adavosertib exhibited synergistic antiproliferative activities both in vitro and in vivo, irrespective of TP53, STK11, and KEAP1 co-mutation profiles. WEE1 inhibition potentiated MCL-1-mediated apoptosis in sotorasib-treated cancer cells. Mechanistically, the combination downregulated MCL-1 protein levels by attenuating de novo translation and enhancing its degradation. WEE1 overexpression conferred resistance against sotorasib via MCL-1 upregulation. Moreover, cells that acquired sotorasib resistance profoundly upregulated both WEE1 and MCL-1 proteins, highlighting WEE1 as a crucial driver of sotorasib resistance. Importantly, WEE1 inhibition re-sensitized resistant cells to sotorasib treatment. The current findings demonstrate that combined inhibition of KRAS^G12C and WEE1 not only exhibits synergistic antitumor efficacy but also overcomes resistance to KRAS^G12C inhibitors, thus representing a novel therapeutic strategy for KRAS^G12C-mutant NSCLC.

Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
Hidenori Kitai, Philip H. Choi, Yu C. Yang, Jacob A. Boyer, Adele Whaley, Priya Pancholi, Claire Thant, Jason Reiter, Kevin Chen, Vladimir Markov, Hirokazu Taniguchi, Rui Yamaguchi, Hiromichi Ebi, James Evans, Jingjing Jiang, Bianca Lee, David Wildes, Elisa de Stanchina, Jacqueline A. M. Smith, Mallika Singh, Neal Rosen
Nature Communications, 15, 1, Springer Science and Business Media LLC, 19 Jul. 2024
Scientific journal, Abstract

Current KRAS^G12C (OFF) inhibitors that target inactive GDP-bound KRAS^G12C cause responses in less than half of patients and these responses are not durable. A class of RAS^G12C (ON) inhibitors that targets active GTP-bound KRAS^G12C blocks ERK signaling more potently than the inactive-state inhibitors. Sensitivity to either class of agents is strongly correlated with inhibition of mTORC1 activity. We have previously shown that PI3K/mTOR and ERK-signaling pathways converge on key cellular processes and that inhibition of both pathways is required for inhibition of these processes and for significant antitumor activity. We find here that the combination of a KRAS^G12C inhibitor with a selective mTORC1 kinase inhibitor causes synergistic inhibition of Cyclin D1 expression and cap-dependent translation. Moreover, BIM upregulation by KRAS^G12C inhibition and inhibition of MCL-1 expression by the mTORC1 inhibitor are both required to induce significant cell death. In vivo, this combination causes deep, durable tumor regressions and is well tolerated. This study suggests that the ERK and PI3K/mTOR pathways each mitigate the effects of inhibition of the other and that combinatorial inhibition is a potential strategy for treating KRAS^G12C-dependent lung cancer.

Oncogene alterations in non-small cell lung cancer with FGFR1 amplification-novel approach to stratify patients who benefit from FGFR inhibitors.
Kitai H, Hiromichi Ebi
Translational lung cancer research, 08 Mar. 2024
Scientific journal

Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer.
Kosuke Tsuji, Eiki Kikuchi, Yuta Takashima, Tetsuaki Shoji, Hirofumi Takahashi, Shotaro Ito, Daisuke Morinaga, Masahiro Kashima, Makie Maeda, Hidenori Kitai, Junko Kikuchi, Jun Sakakibara-Konishi, Satoshi Konno
Cell cycle (Georgetown, Tex.), 1, 11, 17 Aug. 2023, [International Magazine]
English, Scientific journal, Mitotic slippage, which enables cancer cells to bypass cell death by transitioning from mitosis to the G1 phase without undergoing normal cytokinesis, is one likely mechanism of paclitaxel (PTX) resistance. DNA double-strand breaks (DSBs) in the G1 phase are mainly repaired through non-homologous end joining (NHEJ). Therefore, inhibiting NHEJ could augment the PTX-induced cytotoxicity by impeding the repair of PTX-induced DSBs during the G1 phase following mitotic slippage. We aimed to evaluate the effects of NHEJ inhibition on mitotic slippage after PTX treatment in non-small cell lung cancer (NSCLC). H1299, A549, H1975, and H520 NSCLC cell lines were employed. In addition, A-196 and JQ1 were used as NHEJ inhibitors. H1299 cells were PTX-resistant and exhibited an increased frequency of mitotic slippage upon PTX treatment. NHEJ inhibitors significantly augmented the PTX-induced cytotoxicity, DSBs, and apoptosis in H1299 cells. The newly generated PTX-resistant cells were even more prone to mitotic slippage following PTX treatment and susceptible to the combined therapy. Docetaxel further demonstrated synergistic effects with the NHEJ inhibitor in PTX-resistant cells. NHEJ inhibition may overcome intrinsic or acquired PTX resistance resulting from mitotic slippage by synergistically increasing the cytotoxic effects of antimitotic drugs in NSCLC.

80歳以上の高齢者に対する経気管支生検の安全性と有用性の検討
畠山 酉季, 高島 雄太, 鈴木 孝敏, 棟方 奈菜, 中村 友彦, 高橋 宏典, 古田 恵, 北井 秀典, 庄司 哲明, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 品川 尚文, 今野 哲
気管支学, 45, Suppl., S217, S217, (一社)日本呼吸器内視鏡学会, Jun. 2023
Japanese

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
Hirokazu Taniguchi, Rebecca Caeser, Shweta S. Chavan, Yingqian A. Zhan, Andrew Chow, Parvathy Manoj, Fathema Uddin, Hidenori Kitai, Rui Qu, Omar Hayatt, Nisargbhai S. Shah, Álvaro Quintanal Villalonga, Viola Allaj, Evelyn M. Nguyen, Joseph Chan, Adam O. Michel, Hiroshi Mukae, Elisa de Stanchina, Charles M. Rudin, Triparna Sen
Cell Reports, May 2022
Scientific journal

気管支鏡検査におけるFFPE組織検体および細胞検体を用いたROS1融合遺伝子の検査成功率の検証
辻 康介, 榊原 純, 北井 秀典, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 國崎 守, 庄司 哲明, 高島 雄太, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 順子, 菊地 英毅, 品川 尚文, 樋田 泰浩, 加賀 基知三, 大井 優子, 中條 聖子, 畑中 佳奈子, 畑中 豊, 松野 吉宏, 今野 哲
気管支学, 41, 6, 678, 678, (NPO)日本呼吸器内視鏡学会, Nov. 2019
Japanese

Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer
Jun Sakakibara-Konishi, Hidenori Kitai, Yasuyuki Ikezawa, Yutaka Hatanaka, Takaaki Sasaki, Ryohei Yoshida, Shinichi Chiba, Shingo Matsumoto, Koichi Goto, Hidenori Mizugaki, Naofumi Shinagawa
Clinical Lung Cancer, 20, 5, e555, e559, Elsevier BV, Sep. 2019
Scientific journal

Response to First-Line Osimertinib Treatment in Non–Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations
Tomoo Ikari, Jun Sakakibara-Konishi, Gaku Yamamoto, Hidenori Kitai, Hidenori Mizugaki, Hajime Asahina, Eiki Kikuchi, Naofumi Shinagawa
Clinical Lung Cancer, 20, 4, e531, e533, Elsevier BV, Jul. 2019
Scientific journal

Response of BRAFV600E-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment
Gaku Yamamoto, Jun Sakakibara-Konishi, Tomoo Ikari, Hidenori Kitai, Hidenori Mizugaki, Hajime Asahina, Eiki Kikuchi, Naofumi Shinagawa
Journal of Thoracic Oncology, 14, 5, e97, e99, Elsevier BV, May 2019
Scientific journal

Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers
Hiroshi Kotani, Yuta Adachi, Hidenori Kitai, Shuta Tomida, Hideaki Bando, Anthony C. Faber, Takayuki Yoshino, Dominic C. Voon, Seiji Yano, Hiromichi Ebi
Oncogene, 37, 13, 1775, 1787, Springer Science and Business Media LLC, 19 Jan. 2018
Scientific journal

A clinical analysis of 10 cases with oligometastases of non-small cell carcinoma
Kunisaki, M., Sakakibara, J., Kikuchi, H., Kitai, H., Mizugaki, H., Asahina, H., Kikuchi, E., Shinagawa, N., Nishimura, M.
Japanese Journal of Lung Cancer, 58, 7, 2018
Scientific journal

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
Kyung-A Song, Matthew J. Niederst, Timothy L. Lochmann, Aaron N. Hata, Hidenori Kitai, Jungoh Ham, Konstantinos V. Floros, Mark A. Hicks, Haichuan Hu, Hillary E. Mulvey, Yotam Drier, Daniel A.R. Heisey, Mark T. Hughes, Neha U. Patel, Elizabeth L. Lockerman, Angel Garcia, Shawn Gillepsie, Hannah L. Archibald, Maria Gomez-Caraballo, Tara J. Nulton, Brad E. Windle, Zofia Piotrowska, Sinem E. Sahingur, Shirley M. Taylor, Mikhail Dozmorov, Lecia V. Sequist, Bradley Bernstein, Hiromichi Ebi, Jeffrey A. Engelman, Anthony C. Faber
Clinical Cancer Research, 24, 1, 197, 208, American Association for Cancer Research (AACR), 01 Jan. 2018
Scientific journal

Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer
Yuta Adachi, Kazuyoshi Watanabe, Kenji Kita, Hidenori Kitai, Hiroshi Kotani, Yuki Sato, Naohiko Inase, Seiji Yano, Hiromichi Ebi
Carcinogenesis, 38, 11, 1063, 1072, Oxford University Press (OUP), 31 Aug. 2017
Scientific journal

Improvements of visual function and outer retinal morphology following spontaneous regression of cancer in anti-recoverin cancer-associated retinopathy
Suimon, Y., Saito, W., Hirooka, K., Kanda, A., Kitai, H., Sakakibara-Konishi, J., Ishida, S.
American Journal of Ophthalmology Case Reports, 5, 137, 140, 2017, [International Magazine]
English, Scientific journal

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
Kitai, H., Ebi, H.
Small GTPases, 8, 3, 2017
Scientific journal

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
Hidenori Kitai, Hiromichi Ebi, Shuta Tomida, Konstantinos V. Floros, Hiroshi Kotani, Yuta Adachi, Satoshi Oizumi, Masaharu Nishimura, Anthony C. Faber, Seiji Yano
Cancer Discovery, 6, 7, 754, 769, American Association for Cancer Research (AACR), 30 Jun. 2016
Scientific journal

Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration.
Azusa Tanimoto, Takeuchi S, Hiroshi Yaegashi, Kotani H, Kitai H, Nanjo S, Hiromichi Ebi, Yamashita K, Mouri H, Ohtsubo K, Ikeda H, Yano S
Molecular and clinical oncology, 25 Jan. 2016
Scientific journal, A 76-year-old female in whom a renal cell carcinoma (RCC) lesion was resected 19 years previously presented to our hospital with cognitive dysfunction. Magnetic resonance imaging and computed tomography revealed nodules in the brain, lung, adrenal gland and a pelvic osteolytic lesion. To identify the primary cancer site, the present study performed endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of the left adrenal lesion. Consequently, the pathological findings of the tissue obtained by EUS-FNA were similar to those of the previous nephrectomy specimen, revealing that the adrenal lesion was the recurrence of RCC. The majority of the metastatic lesions in the patient were reduced in size by the multiple kinase inhibitor, pazopanib. Contralateral adrenal metastasis of RCC is rare and the use of EUS-FNA in the diagnosis of adrenal lesions remains to be elucidated. This is a rare case of adrenal lesion, diagnosed by EUS-FNA. Therefore, EUS-FNA is considered to be a useful diagnostic modality of adrenal metastases from unidentified primary tumor types.

Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression
H Kotani, H Ebi, H Kitai, S Nanjo, K Kita, T G Huynh, A Ooi, A C Faber, M Mino-Kenudson, S Yano
Oncogene, 35, 27, 3587, 3597, Springer Science and Business Media LLC, 09 Nov. 2015
Scientific journal

Spontaneous regression of small cell lung cancer combined with cancer associated retinopathy
Hidenori Kitai, Jun Sakakibara-Konishi, Satoshi Oizumi, Yoshihiko Hirohashi, Wataru Saito, Atsuhiro Kanda, Noriyuki Sato, Masaharu Nishimura
LUNG CANCER, 87, 1, 73, 76, Jan. 2015, [Peer-reviewed], [International Magazine]
English, Scientific journal

当院における悪性胸膜中皮腫27例の検討　　　　　　　　　　　　　　　
菊池 創, 朝比奈 肇, 北井 秀典, 池澤 靖元, 高階 太一, 品川 尚文, 榊原 純, 大泉 聡史, 西村 正治, 樋田 泰浩, 加賀 基知三, 井上 哲也, 加藤 徳雄
肺癌, 53, 7, 918, 918, (NPO)日本肺癌学会, Dec. 2013, [Peer-reviewed]
Japanese

ロルラチニブ治療後にクリゾチニブ再投与が著効したALK融合遺伝子陽性肺腺癌の1例　　　　　　　　　　　　　　　
辻 康介, 榊原 純, 北井 秀典, 水柿 秀紀, 朝比奈 肇, 菊地 順子, 菊地 英毅, 品川 尚文, 今野 哲, 池澤 靖元, 畑中 豊, 佐々木 高明, 吉田 遼平, 千葉 伸一, 松本 慎吾, 後藤 功一, 肺癌, 59, 7, 1200, 1200, Dec. 2019
(NPO)日本肺癌学会, Japanese

気管支鏡検査におけるFFPE組織検体および細胞検体を用いたROS1融合遺伝子の検査成功率の検証
辻 康介, 榊原 純, 北井 秀典, 猪狩 智生, 佐藤 峰嘉, 高橋 宏典, 國崎 守, 庄司 哲明, 高島 雄太, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 順子, 菊地 英毅, 品川 尚文, 樋田 泰浩, 加賀 基知三, 大井 優子, 中條 聖子, 畑中 佳奈子, 畑中 豊, 松野 吉宏, 今野 哲, 気管支学, 41, 6, 678, 678, Nov. 2019
(NPO)日本呼吸器内視鏡学会, Japanese

当科における非小細胞肺癌化学放射線療法後のデュルバルマブ使用症例の後方視的検討
辻 康介, 水柿 秀紀, 猪狩 智生, 佐藤 峰嘉, 國崎 守, 北井 秀典, 朝比奈 肇, 菊地 順子, 菊地 英毅, 榊原 純, 品川 尚文, 日本サルコイドーシス/肉芽腫性疾患学会雑誌, 39, 1-2, 116, 116, Oct. 2019
日本サルコイドーシス, Japanese

当院におけるFFPE検体、細胞診検体を用いたROS1融合遺伝子の検査成功率の検証　　　　　　　　　　　　　　　
北井 秀典, 榊原 純, 高橋 宏典, 國崎 守, 庄司 哲明, 高島 雄太, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 品川 尚文, 畑中 佳奈子, 畑中 豊, 松野 吉宏, 大井 優子, 肺癌, 59, 1, 112, 112, Feb. 2019
(NPO)日本肺癌学会, Japanese

手掌筋転移に対して放射線照射後に免疫チェックポイント阻害薬が著効した1例　　　　　　　　　　　　　　　
高橋 宏典, 水柿 秀紀, 國崎 守, 高島 雄太, 古田 恵, 庄司 哲明, 佐々木 真知子, 北井 秀典, 朝比奈 肇, 菊地 順子, 菊地 英毅, 榊原 純, 品川 尚文, 肺癌, 59, 1, 112, 112, Feb. 2019
(NPO)日本肺癌学会, Japanese

脳転移を伴う非小細胞肺癌に対する免疫チェックポイント阻害剤投与例の後方視的検討　　　　　　　　　　　　　　　
佐藤 峰嘉, 朝比奈 肇, 高橋 宏典, 國崎 守, 古田 恵, 庄司 哲明, 高島 雄太, 佐々木 真知子, 北井 秀典, 水柿 秀紀, 菊地 英毅, 菊地 順子, 榊原 純, 品川 尚文, 肺癌, 59, 1, 112, 113, Feb. 2019
(NPO)日本肺癌学会, Japanese

DirectPath ver2.0における肺血管抽出機能の有用性の検討
國崎 守, 品川 尚文, 高橋 宏典, 高島 雄太, 古田 恵, 庄司 哲明, 北井 秀典, 佐々木 真知子, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 気管支学, 41, 1, 90, 90, 25 Jan. 2019
(NPO)日本呼吸器内視鏡学会, Japanese

気管支鏡下生検検体におけるPD-L1発現評価の後ろ向き検討
高橋 宏典, 品川 尚文, 畑中 豊, 國崎 守, 古田 恵, 高島 雄太, 庄司 哲明, 北井 秀典, 菊池 創, 水柿 秀紀, 朝比奈 肇, 菊地 順子, 菊地 英毅, 松野 吉宏, 榊原 純, 気管支学, 41, 1, 91, 91, 25 Jan. 2019
(NPO)日本呼吸器内視鏡学会, Japanese

Successful Treatment of Gefitinib Administration Through a Nasogastric Tube in a Patient with EGFR Mutation-positive Lung Adenocarcinoma Associated with Tracheoesophageal Fistula
Furuta Megumi, Nishimura Masaharu, Sakakibara Jun, Ogi Takahiro, Abe Tomoe, Kitai Hidenori, Shimizu Kaoruko, Asahina Hajime, Shinagawa Naofumi, Oizumi Satoshi, The Journal of the Japan Society for Respiratory Endoscopy, 41, 1, 55, 60, 25 Jan. 2019
<p><b><i>Background.</i></b> Gefitinib has been reported to be effective for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (<i>EGFR</i>) mutations even with poor performance status (PS). Here, we report a case of successful treatment of gefitinib administration through a nasogastric tube in a patient with <i>EGFR</i> mutation-positive lung adenocarcinoma associated with bronchoesophageal fistula. <b><i>Case.</i></b> A 69-year-old woman complained of dyspnea and was admitted to an emergency hospital. Imaging tests revealed tracheal stenosis caused by mediastinal lymph node enlargement. She was transferred to our hospital under mechanical ventilation because of progressive severe hypoxia. Although tracheal stenosis improved by central necrosis of mediastinal lymph node metastasis on admission, tracheoesophageal fistula was observed. She was diagnosed with primary lung adenocarcinoma (cT4N2M1a, stage IV) and the <i>EGFR</i> mutation exon 19 deletion was detected. Because it was impossible to administer tracheoesophageal fistula orally, gefitinib was administered through a nasogastric tube. The fistula was closed three weeks after gefitinib administration and the tumor decreased in size, which resulted in improvement in PS. <b><i>Conclusion.</i></b> Gefitinib administration through a nasogastric tube is useful for patients that are positive for <i>EGFR</i> mutations with tracheoesophageal fistula and poor PS. </p>, 特定非営利活動法人 日本呼吸器内視鏡学会, Japanese

T790M検索を目的とした組織再生検及び血漿検査の後方視的検討
猪狩智生, 北井秀典, 高橋宏典, 國崎守, 庄司哲明, 古田恵, 高島雄太, 佐々木真知子, 水柿秀紀, 朝比奈肇, 菊地英毅, 菊地順子, 榊原純, 畑中豊, 松野吉宏, 品川尚文, 日本肺癌学会総会号, 58, 6, 635, 635, Oct. 2018
(NPO)日本肺癌学会, Japanese

当科における免疫チェックポイント阻害剤治療の現状
高橋宏典, 水柿秀紀, 國崎守, 高島雄太, 古田恵, 庄司哲明, 佐々木真知子, 北井秀典, 朝比奈肇, 菊地順子, 菊地英毅, 榊原純, 品川尚文, 日本肺癌学会総会号, 58, 6, 644, 644, Oct. 2018
(NPO)日本肺癌学会, Japanese

DirectPath ver2.0における肺血管抽出機能の有用性の検討
國崎守, 品川尚文, 高橋宏典, 高島雄太, 古田恵, 庄司哲明, 北井秀典, 佐々木真知子, 菊池創, 水柿秀紀, 朝比奈肇, 菊地英毅, 菊地順子, 榊原純, 西村正治, 気管支学, 40, Suppl., S252, S252, 01 May 2018
(NPO)日本呼吸器内視鏡学会, Japanese

超音波気管支鏡ガイド下針生検用の新しい吸引生検針の使用経験　　　　　　　　　　　　　　　
高橋 宏典, 品川 尚文, 阿部 結希, 小熊 昂, 國崎 守, 古田 恵, 高島 雄太, 庄司 哲明, 佐々木 真知子, 北井 秀典, 菊池 創, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 西村 正治, 気管支学, 40, 1, 69, 69, Jan. 2018
(NPO)日本呼吸器内視鏡学会, Japanese

当科におけるEGFR遺伝子変異陽性非小細胞肺癌の再生検の検討
佐々木真知子, 品川尚文, 國崎守, 庄司哲明, 高島雄太, 古田恵, 菊池創, 北井秀典, 朝比奈肇, 菊地英毅, 菊地順子, 榊原純, 西村正治, 気管支学, 40, 1, 68(J‐STAGE), 2018
Japanese

ニボルマブ投与後に間質性腎炎を発症した膜性腎症合併肺癌の1例　　　　　　　　　　　　　　　
佐々木 真知子, 水柿 秀紀, 高橋 宏典, 國崎 守, 庄司 哲明, 高島 雄太, 古田 恵, 菊池 創, 北井 秀典, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 品川 尚文, 西村 正治, 近藤 桂一, 深澤 雄一郎, 肺癌, 57, 7, 916, 916, Dec. 2017
(NPO)日本肺癌学会, Japanese

血漿中にEGFR T790M遺伝子変異を認め、オシメルチニブ治療にmixed responseを示したEGFR遺伝子変異陽性非小細胞肺癌の1例　　　　　　　　　　　　　　　
小田 義崇, 國崎 守, 菊地 英毅, 阿部 結希, 小熊 昂, 高橋 宏典, 佐々木 真知子, 北井 秀典, 水柿 秀紀, 朝比奈 肇, 菊地 順子, 榊原 純, 品川 尚文, 西村 正治, 肺癌, 57, 7, 916, 917, Dec. 2017
(NPO)日本肺癌学会, Japanese

EUSにおける主膵管拡張を契機とし、連続膵液細胞診(serial pancreatic juice aspiration cytological examination:SPACE)にて診断された膵上皮内癌の1切除例
大坪 公士郎, 足立 雄太, 谷口 寛和, 谷本 梓, 北井 秀典, 小谷 浩, 西山 明宏, 南條 成輝, 渡辺 一孝, 竹内 伸司, 衣斐 寛倫, 山田 忠明, 毛利 久継, 山下 要, 牧野 勇, 宮下 知治, 田島 秀浩, 太田 哲生, 井上 大, 蒲田 敏文, 池田 博子, 矢野 聖二, ENDOSCOPIC FORUM for digestive disease, 32, 1, 67, 67, May 2016
(株)癌と化学療法社, Japanese

Cisplatin/Irinotecan併用療法が有効であった盲腸原発神経内分泌癌多発肝転移の3例　　　　　　　　　　　　　　　
山下 要, 小谷 浩, 衣斐 寛倫, 谷本 梓, 足立 雄太, 谷口 寛和, 北井 秀典, 西山 明宏, 渡辺 一孝, 南條 成輝, 竹内 伸司, 毛利 久継, 大坪 公士郎, 矢野 聖二, 日本癌治療学会誌, 50, 3, 2477, 2477, Sep. 2015
(一社)日本癌治療学会, Japanese

自然退縮を認めた,癌関連網膜症合併小細胞肺癌の1例
中村順一, 北井秀典, 榊原純, 水柿秀紀, 大泉聡史, 西村正治, 廣橋良彦, 佐藤昇志, 齋藤航, 神田敦宏, 肺癌(Web), 54, 7, 990(J‐STAGE), 990, Dec. 2014
(NPO)日本肺癌学会, Japanese

O22-6 肺末梢病変に対する挿入部回転機能付き細径気管支鏡の有用性の検討(気管支鏡 新技術,一般演題(口演),第37回日本呼吸器内視鏡学会学術集会)
北井 秀典, 品川 尚文, 菊池 創, 庄司 哲明, 高階 太一, 池澤 靖元, 朝比奈 肇, 榊原 純, 大泉 聡史, 西村 正治, 気管支学, 36, 0, S185, 2014
特定非営利活動法人 日本呼吸器内視鏡学会, Japanese

O9-1 当院で経験した中枢性気道狭窄症例の検討(Interventional pulmonology,一般演題(口演),第37回日本呼吸器内視鏡学会学術集会)
菊池 創, 品川 尚文, 北井 秀典, 高階 太一, 池澤 靖元, 朝比奈 肇, 榊原 純, 大泉 聡史, 西村 正治, 気管支学, 36, 0, S154, 2014
特定非営利活動法人 日本呼吸器内視鏡学会, Japanese

当院における皮膚筋炎・多発筋炎(DM/PM)合併肺癌の検討
松本宗大, 朝比奈肇, 菊池創, 北井秀典, 品川尚文, 榊原純, 大泉聡史, 西村正治, 肺癌(Web), 53, 7, 917-918(J-STAGE), 918, Dec. 2013
(NPO)日本肺癌学会, Japanese

当院における悪性胸膜中皮腫27例の検討
菊池創, 朝比奈肇, 北井秀典, 池澤靖元, 高階太一, 品川尚文, 榊原純, 大泉聡史, 西村正治, 樋田泰浩, 加賀基知三, 井上哲也, 加藤徳雄, 肺癌(Web), 53, 7, 918(J-STAGE), 918, Dec. 2013
(NPO)日本肺癌学会, Japanese

当院における非小細胞肺癌に対するweekly nab‐PTX+CBDCA併用療法の検討
庄司哲明, 朝比奈肇, 大橋洋介, 松本宗大, 北井秀典, 菊池創, 照井浩也, 榊原純, 品川尚文, 大泉聡史, 西村正治, 肺癌(Web), 53, 7, 918(J-STAGE), 918, Dec. 2013
(NPO)日本肺癌学会, Japanese

気管支形成術後の縫合糸が原因と考えられた炎症性肉芽腫により気管支狭窄を繰り返した1例
北井秀典, 品川尚文, 菊池創, 高階太一, 池澤靖元, 朝比奈肇, 榊原純, 大泉聡史, 西村正治, 気管支学, 35, 6, 683, 684, 25 Nov. 2013
特定非営利活動法人 日本呼吸器内視鏡学会, Japanese

ENDOBRONCHIAL ULTRASONOGRAPHY WITH A GUIDE SHEATH IN THE DIAGNOSIS OF BENIGN PERIPHERAL LESIONS
Alice P. S. Cheung, Naofumi Shinagawa, Hidenori Kitai, Noriyuki Yamada, Hajime Asahina, Jun K. Sakakibara, Satoshi Oizumi, Masaharu Nishimura, RESPIROLOGY, 18, 56, 56, Nov. 2013
English, Summary international conference

EFFICACY OF PEMETREXED IN ADVANCED NON-SMALL CELL LUNG CANCER WITH ASYMPTOMATIC BRAIN METASTASES
Hidenori Kitai, Hajime Asahina, Taichi Takashina, Yasuyuki Ikezawa, Jyunn Sakakibara-Konishi, Naofumi Shinagawa, Satoshi Oizumi, Masaharu Nishimura, JOURNAL OF THORACIC ONCOLOGY, 8, S867, S867, Nov. 2013
English, Summary international conference

当院における皮膚筋炎・多発筋炎(DM/PM)合併肺癌の検討
松本宗大, 朝比奈肇, 北井秀典, 菊地創, 池澤靖元, 高階太一, 品川尚文, 榊原純, 大泉聡史, 西村正治, 日本肺癌学会総会号, 54th, 5, 546, 546, 05 Oct. 2013
(NPO)日本肺癌学会, Japanese

肺末梢病変に対する挿入部回転機能付き細径気管支鏡,極細径気管支鏡の有用性の検討
北井秀典, 品川尚文, 菊池創, 高階太一, 池澤靖元, 朝比奈肇, 榊原純, 大泉聡史, 西村正治, 日本肺癌学会総会号, 54th, 5, 585, 585, 05 Oct. 2013
(NPO)日本肺癌学会, Japanese

当院における非小細胞肺癌に対するweekly nab‐PTX+CBDCA併用療法の検討
庄司哲明, 朝比奈肇, 大橋洋介, 松本宗大, 北井秀典, 照井浩也, 菊池創, 榊原純, 品川尚文, 大泉聡史, 西村正治, 日本肺癌学会総会号, 54th, 5, 608, 608, 05 Oct. 2013
(NPO)日本肺癌学会, Japanese

当院における悪性胸膜中皮腫27例の検討
菊池創, 朝比奈肇, 北井秀典, 池澤靖元, 高階太一, 品川尚文, 榊原純, 大泉聡史, 樋田泰浩, 加賀基知三, 井上哲也, 加藤徳雄, 西村正治, 日本肺癌学会総会号, 53, 5, 382, 382, Oct. 2013
(NPO)日本肺癌学会, Japanese

O15-5 Bf-NAVI(R)における部位別自動抽出能の検討(仮想気管支鏡-2,一般演題口演,第36回日本呼吸器内視鏡学会学術集会)
品川 尚文, 北井 秀典, 池澤 靖元, 高階 太一, 山田 範幸, 朝比奈 肇, 榊原 純, 大泉 聡史, 西村 正治, 気管支学, 35, 0, S174, 2013
特定非営利活動法人 日本呼吸器内視鏡学会, Japanese

O5-5 超音波気管支鏡ガイド下針生検における組織診の有用性の検討(EBUS-1,一般演題口演,第36回日本呼吸器内視鏡学会学術集会)
北井 秀典, 品川 尚文, 阿部 智絵, 高階 太一, 池澤 靖元, 山田 範幸, 朝比奈 肇, 榊原 純, 大泉 聡史, 西村 正治, 気管支学, 35, 0, S152, 2013
特定非営利活動法人 日本呼吸器内視鏡学会, Japanese

4.Bf-NAVI^[○!R]における部位別自動抽出能の検討(第35回 日本呼吸器内視鏡学会北海道支部会)
品川 尚文, 北井 秀典, 池澤 靖元, 高階 太一, 朝比奈 肇, 榊原 純, 大泉 聡史, 西村 正治, 気管支学, 35, 6, 682, 683, 2013
特定非営利活動法人 日本呼吸器内視鏡学会, Japanese

脳転移を有する非小細胞肺癌に対するPemetrexedを含む化学療法の有効性の検討
北井秀典, 朝比奈肇, 大泉聡史, 高階太一, 池澤靖元, 山田範幸, 榊原純, 品川尚文, 西村正治, 肺癌, 52, 5, 601, 601, 05 Oct. 2012
(NPO)日本肺癌学会, Japanese

ひと・AI/DX・しくみの三位一体的整備による次世代AI活用・データ駆動・情報循環型医学研究の戦略的推進　　　　　　　　　　　　　　　
革新的研究開発推進基金補助金
Oct. 2025 - Mar. 2028
国立研究開発法人日本医療研究開発機構, Principal investigator, 25147880

Uncovering the mechanisms of adaptive resistance to KRAS-specific inhibitor and development of novel therapeutic strategies in KRAS-mutant lung cancer
Grants-in-Aid for Scientific Research
01 Apr. 2024 - 31 Mar. 2027
北井 秀典
Japan Society for the Promotion of Science, Grant-in-Aid for Early-Career Scientists, Hokkaido University, 24K19078